Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ATOSSA THERAPEUTICS, INC. Director's Dealing 2016

Feb 17, 2016

34113_dirs_2016-02-17_f6bd7727-d656-4003-b224-64a28d776d76.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ATOSSA GENETICS INC (ATOS)
CIK: 0001488039
Period of Report: 2016-02-16

Reporting Person: Chen Shu-Chih (Director, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-02-16 Common Stock P 15000 $0.53 Acquired 4333315 Indirect

Footnotes

F1: Represents 15,000 shares purchased in an at-market transaction directly from Atossa Genetics, Inc.

F2: Consists of 4,333,315 shares of common stock owned by Ensisheim Partners, LLC ("Ensisheim"). Shu-Chih Chen, Ph.D. and Steven C. Quay, M.D., Ph.D., share voting and investment power over the securities held by Ensisheim. Ensisheim is solely owned and controlled by Drs. Chen and Quay, and, as a result, Drs. Chen and Quay are deemed to be beneficial owners of the shares held by this entity.